An Open Trial of Metacognitive Remediation Therapy and Pharmacotherapy to Promote Smoking Cessation among Individuals with Psychotic-Spectrum Disorders.

Nicholas J K Breitborde Brittney Keller-HamiltonAubrey M MoeJacob G Pine Nicholas Nelson David M Weiss Tory H Hogan Amanda J Quisenberry Andreas A Teferra Amy K Ferketich

Published in: Journal of smoking cessation (2021)

The results from the current study suggest cautious optimism with regard to the use of MCR-Q in combination with medication for individuals with psychotic-spectrum disorders who want to quit smoking.

Keyphrases

double blind
phase iii
smoking cessation
clinical trial
replacement therapy
phase ii
bipolar disorder
study protocol
escherichia coli
healthcare
open label
stem cells
emergency department
klebsiella pneumoniae
adverse drug
mesenchymal stem cells
bone marrow